Active Biotech AB (SE:ACTI)
:ACTI
Want to see SE:ACTI full AI Analyst Report?
Top Page
Active Biotech AB
(ACTI)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr6.00
▲(14900.00% Upside)
Action:Reiterated
Date:06/03/26
The score is held down primarily by continued losses, no revenue, and ongoing cash burn, despite improvement versus prior peaks. A low-debt balance sheet provides some stability, while technical indicators and valuation inputs offer only modest support and remain constrained by weak profitability.
Positive Factors
Low leverage / conservative balance sheet
Very low leverage meaningfully reduces financial risk and preserves optionality for funding R&D or partnering. This durable credit strength lowers default risk, improves negotiation power with partners and investors, and supports operations for several quarters absent large new cash needs.
Negative Factors
No revenue / persistent heavy losses
Lack of revenue means the business cannot self-fund operations and remains fully reliant on external financing or licensing. Persistent losses undermine long-term viability if new financing or partner deals are delayed, increasing dilution or the need to cut programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / conservative balance sheet
Very low leverage meaningfully reduces financial risk and preserves optionality for funding R&D or partnering. This durable credit strength lowers default risk, improves negotiation power with partners and investors, and supports operations for several quarters absent large new cash needs.
Read all positive factors
Active Biotech AB (ACTI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr154.47M
Dividend YieldN/A
Average Volume (3M)4.56M
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue GrowthN/A
EPS Growth49.74%
CountrySE
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding26,360,670
10 Day Avg. Volume2,218,804
30 Day Avg. Volume4,558,826
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)111.47
Price to Sales (P/S)0.00
P/FCF Ratio-191.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr21.50M
Active Biotech AB Business Overview & Revenue Model
Company Description
Active Biotech AB (publ) is a Swedish biotechnology firm focused on developing pharmaceutical treatments for oncology and immunological conditions. Its product pipeline features Tasquinimod, a small molecule immunomodulator currently in Phase Ib/I...
How the Company Makes Money
null...
Active Biotech AB Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.60M | -1.60M | -1.64M | -1.68M | -1.49M | -1.28M |
| EBITDA | -33.80M | -36.00M | -38.30M | -43.89M | -56.67M | -48.52M |
| Net Income | -34.70M | -37.30M | -39.40M | -45.80M | -58.69M | -49.88M |
Balance Sheet | ||||||
| Total Assets | 58.20M | 70.20M | 43.20M | 44.05M | 51.01M | 56.80M |
| Cash, Cash Equivalents and Short-Term Investments | 53.30M | 65.10M | 27.40M | 36.22M | 41.80M | 53.13M |
| Total Debt | 100.00K | 1.74M | 3.18M | 4.54M | 6.04M | 986.00K |
| Total Liabilities | 11.00M | 14.60M | 11.13M | 13.38M | 16.49M | 10.13M |
| Stockholders Equity | 47.20M | 55.60M | 32.07M | 30.67M | 34.51M | 46.67M |
Cash Flow | ||||||
| Free Cash Flow | -31.30M | -32.40M | -40.40M | -45.74M | -55.09M | -46.17M |
| Operating Cash Flow | -31.30M | -32.40M | -40.40M | -45.74M | -54.85M | -46.17M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -245.00K | 0.00 |
| Financing Cash Flow | 58.50M | 70.10M | 31.60M | 40.16M | 43.76M | 73.09M |
Active Biotech AB Technical Analysis
Negative
0.04
Price Trends
6.50
Negative
5.47
Positive
6.90
Negative
Market Momentum
-0.12
Positive
44.15
Neutral
17.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACTI, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 6.43, below the 50-day MA of 6.50, and below the 200-day MA of 6.90, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 44.15 is Neutral, neither overbought nor oversold. The STOCH value of 17.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACTI.
Active Biotech AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr221.46M | -3.41 | -51.35% | ― | ― | 9.40% | |
44 Neutral | kr154.47M | -446.69 | -1291.15% | ― | ― | 49.74% | |
44 Neutral | kr169.81M | -1.51 | -199.86% | ― | -6.59% | 27.05% | |
43 Neutral | kr172.25M | -3.40 | ― | ― | -36.27% | 0.77% | |
42 Neutral | kr189.29M | -9.79 | -59.78% | ― | ― | 43.30% |
* Healthcare Sector Average
SE:ACTI
Active Biotech AB
6.10
-9.23
-60.24%
SE:MVIR
Medivir AB
1.62
>-0.01
-0.49%
SE:ISOFOL
Isofol Medical AB
0.68
-0.30
-31.02%
SE:XINT
Xintela AB
0.19
-0.25
-57.24%
SE:ELIC
Elicera Therapeutics AB
2.70
-2.52
-48.29%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.24
-5.02
-80.14%
Active Biotech AB Corporate Events
Active Biotech Sets June Timetable for 1:100 Reverse Share Split
May 28, 2026
Active Biotech AB has set the timetable for a 1-for-100 reverse share split approved at its 2026 Annual General Meeting, consolidating every hundred existing shares into one new share. Trading in the shares under the new structure and ISIN code SE...
Active Biotech AGM Backs Reverse Share Split and Expands Capital Raising Mandate
May 20, 2026
Active Biotech’s annual general meeting approved a series of governance and capital measures, including the decision not to distribute a dividend for the 2025 financial year and to carry forward the accumulated loss, while granting discharge...
Active Biotech Cleared to Resume Tasquinimod Myelofibrosis Trial in Europe
May 13, 2026
Active Biotech has received approval from European regulatory authorities and ethics committees to resume patient enrolment in the HOVON 172 MF proof‑of‑concept study of tasquinimod in myelofibrosis, conducted within the HOVON network ...
Active Biotech’s LION Study Backs Laquinimod’s Potential in Posterior Eye Disease
Apr 20, 2026
Active Biotech has reported that results from its phase I LION study of topical laquinimod eye drops have been published in Ophthalmology Science, demonstrating dose‑related penetration of the drug into both the anterior and posterior segmen...
Active Biotech Calls 2026 AGM, Maintains Board and Withholds Dividend
Apr 17, 2026
Active Biotech AB has called its annual general meeting for May 20, 2026, in Lund, setting the record date for shareholder participation at May 11 and confirming that it has 2,636,067,170 shares outstanding. The board proposes that no dividend be ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.